 |
|
Treatment of Primary Syphilis with Synnematin BReport of a Case
A. H. WHEELER, Ph.D.;
KENNETH JAMES, M.D.;
WALKER LEA, M.D.;
A. C. CURTIS, M.D.
AMA Arch Derm. 1957;76(6):735-736.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
|
|
The antibiotic synnematin, isolated by Gottshall et al.,1 is produced by the mold Cephalosporium salmosynematum. It has been separated into components A and B by Olson, Jennings, and Junek.2 Synnematin B is active primarily against Gram-negative organisms, including Salmonella, some strains of Proteus, and strains of Shigella and Neisseria. Toxicity by intramuscular injection is reportedly negligible, both in animal experiments and in clinical studies of Salmonella infections.3,4 In a recent paper presented in the Proceedings of the Fourth Annual Symposium on Antibiotics a member of the Abbott Laboratories reported that synnematin B was seven times less toxic than penicillin in animals.5 The antibiotic has not been crystallized, and all material available for use was less than 50% pure.*
In a personal communication to one of us (A. H. W.)5 it was called to our attention that two cases of pinta had been cleared
. . . [Full Text PDF of this Article]
Author Affiliations
Ann Arbor, Mich.
From the Department of Dermatology and Syphilology, University of Michigan Hospital, (Dr. A. C. Curtis, Chairman), Ann Arbor, Mich.
Footnotes
Submitted for publication July 2, 1957.
This paper is an excerpt of data presented at the Eighth Annual Symposium on Recent Advances in the Study of Venereal Diseases, U. S. Department of Health, Education and Welfare, Washington, D. C., April 24-25, 1957.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
